DMD Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on October 12, 2005; DOI: 10.1124/dmd.105.006221

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.006221v1
34/1/61    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franzen, A.
Right arrow Articles by Brittebo, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franzen, A.
Right arrow Articles by Brittebo, E.


Received for publication July 1, 2005.
Revised September 30, 2005.
Accepted for publication October 7, 2005.

CYP2A5-MEDIATED ACTIVATION AND EARLY ULTRASTRUCTURAL CHANGES IN THE OLFACTORY MUCOSA: STUDIES ON 2,6-DICHLOROPHENYL METHYLSULPHONE

Anna Franzen 1, Carina Carlsson 2, Veronica Hermansson 3, Matti Lang 4, Eva Brittebo 4*

1 Pharmaceutical biosciences, Uppsala University 2 Swedish medical products agency 3 dept of environmental toxicology, Uppsala University 4 dept of pharmaceutical biosciences, Uppsala University

* Address correspondence to: E-mail: eva.brittebo{at}farmbio.uu.se

Abstract

2,6-Dichlorophenyl methylsulphone (2,6-diClPh-MeSO2) is a potent olfactory toxicant reported to induce endoplasmic reticulum (ER) stress, caspase activation and extensive cell death in mice. The aim of the present study was to examine cytochrome P450 (CYP) dependent bioactivation, non-protein sulphydryl (NP-SH) levels and early ultrastructural changes in mouse olfactory mucosa following an ip injection of 2,6-diClPh-MeSO2 (32 mg/kg). A high covalent binding of 2,6-diClPh-14C-MeSO2 in olfactory mucosa S9-fraction was observed and the CYP2A5/CYP2G1 substrates coumarin and dichlobenil significantly decreased the binding whereas the CYP2E1 substrate chlorzoxazone had no effects. An increased bioactivation was detected in liver microsomes of mice pretreated with pyrazole, known to induce CYP2A4, 2A5, 2E1 and 2J, and addition of chlorzoxazone reduced this binding. 2,6-DiClPh-14C-MeSO2 showed a marked covalent binding to microsomes of recombinant yeast cells expressing mouse CYP2A5 or human CYP2A6 compared to wild type. One and 4 hr after a single injection of 2,6-diClPh-MeSO2, the NP-SH levels in the olfactory mucosa were significantly reduced compared to control whereas there was no change in the liver. Ultrastructural studies revealed that ER, mitochondria and secretory granules in nonneuronal cells were early targets 1 h after injection. We propose that lesions induced by 2,6-diClPh-MeSO2 in the mouse olfactory mucosa were initiated by a CYP-mediated bioactivation in the Bowman's glands and depletion of NP-SH levels, leading to disruption of ion homeostasis, organelle swelling, and cell death. The high expression of CYP2A5 in the olfactory mucosa is suggested to play a key role for the tissue-specific toxicity induced by 2,6-diClPh-MeSO2.


Key words: CYP2A, extrahepatic drug metabolism, glutathione, protein binding, toxicity


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
A. M. Jeffrey, M. J. Iatropoulos, and G. M. Williams
Nasal Cytotoxic and Carcinogenic Activities of Systemically Distributed Organic Chemicals
Toxicol Pathol, December 1, 2006; 34(7): 827 - 852.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.